Many advances have been achieved in biliary stenting over the past 30 years. Endoscopic stent placement has become the primary management therapy to relieve obstruction in patients with benign or malignant biliary tract diseases. Compared with plastic stents, a self-expandable metallic stent (SEMS) has been used for management in patients with malignant strictures because of a larger lumen and longer stent patency. Recently, SEMS has been used for various benign biliary strictures and leaks. In this article, we briefly review the characteristics of SEMS as well as complications of stent placement. We review the current guidelines for managing malignant and benign biliary obstructions. Recent developments in biliary stenting are also discussed. Clin Endosc 2016;49:124-130
INTRODUCTION
Biliary obstruction can result from various benign and malignant diseases, including primary pancreaticobiliary cancer, metastatic disease, malignant lymphadenopathy, choledocholithiasis, chronic pancreatitis, and postoperative strictures. 1 Hepatobiliary malignancy causes obstruction in 70% to 90% of patients. For patients with malignant biliary obstruction, curative resection is only possible in less than 20% of candidates because of an inoperable condition secondary to local spread and distant metastases. [1] [2] [3] [4] [5] [6] In addition, benign biliary strictures can cause jaundice, pain, pruritus, hepatocellular dysfunction, biliary cirrhosis, and cholangitis. 3 Endoscopic biliary stenting was first introduced in the early 1980s. 7 In the late 1980s, the self-expandable metallic stent (SEMS) was introduced and has been shown to improve patency better than plastic stents. [8] [9] [10] Since their development, biliary stents have been widely used to manage not only malignant biliary obstruction but also benign biliary diseases. In 2012, the European Society for Gastrointestinal Endoscopy (ESGE) published clinical guidelines for biliary stenting that included the indications, choice of stents, and results (Table  1) . 11, 12 In this article, we review the characteristics of metallic biliary stents and complications of stent placement. We also describe the use of stents in a variety of clinical settings and the technical considerations for stenting. Recent advancements and future directions in biliary stenting including some novel stent designs are also discussed.
SELF-EXPANDING METALLIC STENT
Metallic stents are usually made with cobalt-chromium (stainless steel) or an alloy, including nickel-titanium (nitinol), which is a shape memory alloy. 13, 14 SEMS, which expands to full diameter once it is placed in the body, is widely used. Because the diameter at full SEMS expansion is 6 to 10 mm, the duration of patency is much longer, approximately 10 months. The stent length is typically 4 to 12 cm; however, some manufacturers will create stents of different lengths to order. 13 A biliary SEMS is released by retracting the sheath from a preloaded, through-the-scope delivery system with a diameter of 6 to 8.5 Fr. 7, 12 The primary disadvantage of SEMS is the expense.
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Stents can be classified as either a closed-cell or open-cell type, depending on the lattice structure. Most stents are the closed-cell type. Depending on the weave of the metallic fibers, these stents can be further classified into cross wire, hook wire, or hook and cross wire structures. 15, 16 Most manufacturers use a hook and cross wire structure to take advantage of the positive features of both structures. A Zilver stent is an open-cell type stent that does not shorten. The delivery system diameter is 7 Fr, and it is easy to access the stenotic lesion in the bile duct. However, its expandability is weaker than other products; the restoring force is high, and it is difficult to reposition the stent when trying to modify the position. 15, 16 Ingrowth, in which a tumor grows between the mesh lines of the stent, and overgrowth, in which a tumor blocks either the proximal or distal end of the stent, are primary mechanisms of SEMS occlusion. 7, 15, 16 To overcome these limitations and prolong the patency duration, a covered SEMS (CSEMS) was developed. The covering materials include polyurethane, silicone, and polytetrafluoroethylene, all of which are effective. An uncovered SEMS (USEMS) is completely buried inside the tumor and helps to prevent migration. It can be placed in the intrahepatic duct. 12 Disadvantages of USEMS are that it is impossible to change or remove once placed and early occlusion can occur due to tumor ingrowth. Although a CSEMS could decrease occlusion, many studies have reported no differences in patency duration between CSEMS and USEMS. 11, [17] [18] [19] Furthermore, cholecystitis or pancreatitis can occur because the stent covering blocks the opening of cystic or pancreatic ducts, but this is not largely different from a USEMS. 18, 19 The frequency of stent migration is much higher with CSEMS than with USEMS (Table 2 ).
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EFFICACY AND OUTCOMES
Benign biliary disease
Benign biliary strictures Benign biliary strictures can result from postoperative biliary injuries (mainly cholecystectomy or liver transplantation), chronic pancreatitis, primary sclerosing cholangitis, or other chronic inflammatory disorders. 13 The standard strategy for benign biliary strictures is endoscopic management by place- ment of multiple plastic stents, with or without balloon dilatation, until resolution of the stricture. 21 According to the ESGE guidelines, temporary simultaneous placement of multiple plastic stents for benign common bile duct (CBD) strictures is technically feasible in more than 90% of patients, and endoscopy provides superior long-term stricture resolution; 90% of postoperative injuries and 65% of strictures are related to chronic pancreatitis. 11 The main limitation of the multi-stenting strategy is that the stent should be exchanged periodically (on average, between 3 to 5 sessions) for more than 1 year for complete resolution of the stricture, which increases costs and may decrease patient compliance. 21, 22 Recently, SEMS has become available for various benign biliary strictures. Although USEMS is strongly discouraged in benign biliary strictures, CSEMS, which can be removed using an endoscopic approach, could potentially decrease the number of endoscopic procedures. Technically, it is also easier than insertion of multiple plastic stents. 21 In a recent, large, prospective multinational study, the rates of stricture resolution were 90.5%, 88.0%, and 90.9% for chronic pancreatitis, orthotopic liver transplantation, and cholecystectomy groups, respectively, who underwent scheduled fully CSEMS (FCSEMS). 23 However, CSEMS can increase the risk of stent migration, and pancreatitis is a well-known complication. Cholecystitis and cholangitis due to obstruction of the cystic duct by the inserted stent are not uncommon adverse events. 24 The potential risk of contralateral biliary occlusion could also be a limitation to the use of CSEMS in hilar strictures. 1, 21 Therefore, CSEMS might be a suitable alternative therapeutic option in select conditions only, such as refractory benign biliary stricture or stricture from chronic pancreatitis, especially for calcific pancreatitis, which is difficult to treat, and should not be used routinely. 21, [25] [26] [27] [28] The respective roles of treatment strategies for benign biliary strictures of various causes are shown in Table 3 .
Biliary leaks
Bile leaks could successfully be treated with plastic stent placement with or without sphincterotomy in 70% to 100% of patients. 13, [29] [30] [31] [32] A single plastic stent with or without sphincterotomy could be used first in postoperative bile leaks because the CBD is usually not dilated and an insertion of multiple stents or SEMS is difficult. In case of refractory bile leaks, multiple stents or SEMS could be considered. Some studies with small sample sizes have demonstrated complete resolution of large complex leaks and refractory bile leaks with failed plastic stent placements using partially CSEMS or FCSEMS. [33] [34] [35] The placement of SEMS may reduce the pressure of the sphincter of Oddi and also seal the fistula.
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Biliary stones A previous study reported that biliary stone removal fails 5% to 10% of the time after endoscopic retrograde cholangiopancreatography (ERCP). 12 Biliary stenting can help relieve biliary obstruction by bile drainage and stone dissolution. Short-term plastic stent placement could reduce the size or number of biliary stones and facilitate stone removal in over 90% of cases in subsequent procedures. 13, [37] [38] [39] Cerefice et al. 40 reported a sim- ilar outcome using temporary CSEMS placement for complex biliary stone clearance during initial ERCP after a previous unsuccessful stone extraction.
Bleeding and perforation
Recent studies described the use of CSEMS for hemostasis (mainly postsphincterotomy bleeding). CSEMS works by tamponading the bleeding site and provides simultaneous and effective drainage of the bile duct, especially when occluded with blood clots. 36, 41, 42 Perforations from a guidewire or basket insertion are usually small and can be treated with conservative management. The management of a periampullary perforation remains controversial. Recently, FCSEMS has become a therapeutic option to seal perforations and prevent entry into the perforation site.
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Malignant biliary disease
Distal malignant biliary obstruction Distal malignant biliary obstruction is usually due to pancreatic cancer, distal cholangiocarcinoma, ampullary cancer, and less commonly gallbladder cancer and metastatic diseases. 36 USEMS, partially CSEMS, and FCSEMS are used for palliation of patients with a distal malignant biliary obstruction.
In patients with a prognosis of less than 4 months, plastic stents are a better choice because they are cost-effective and the risk of both migration and occlusion within approximately 3 months is low. 12, 45 If expected survival is more than 4 months; however, a recent meta-analysis reported that, compared with a plastic stent, SEMS in the management of malignant biliary obstruction is associated with significantly longer stent patency, fewer ERCPs, and longer patient survival. 36, 46 A meta-analysis showed no differences between CSEMS and USEMS in the patency rates at 6 or 12 months. There was also no difference in pancreatitis, cholecystitis, perforation, bleeding, cholangitis, length of hospital stay, or number of recurrent biliary obstructions. 47 However, CSEMS is associated with a higher rate of stent migration than USEMS. 47 In a multicenter, randomized controlled trial with 400 patients, there was no significant difference in stent patency between USEMS and CSEMS for distal malignant biliary disease. 18 All of these studies support the guidelines issued by the ESGE in 2012 for nonresectable malignant biliary obstruction and show that plastic stents are a good option when patient prognosis is less than 4 months, while SEMS is a better option if the prognosis is more than 4 months (Table 1) . 11, 12 The guidelines do not identify a benefit for CSEMS over USEMS in the treatment of nonhilar biliary obstructions, 11, 12 and the best choice remains controversial.
Hilar malignant biliary obstruction
Hilar obstruction can be caused by primary tumors such as cholangiocarcinoma (Klatskin tumor), local extension from gallbladder carcinoma, hepatocellular carcinoma, pancreatic cancer, and metastatic diseases or compression from lymph nodes. Tumor resectability should be evaluated using imaging techniques before biliary stenting in malignant hilar obstruction. 11 The benefit of preoperative drainage in malignant hilar obstruction is less clear.
A meta-analysis of 11 studies reported no difference in mortality or length of postoperative stay with and without preoperative biliary drainage in jaundiced patients with hilar cholangiocarcinoma, as well as increased overall rates of postoperative and infectious complications. 48, 49 Therefore, preoperative biliary drainage should not be routinely performed. However, in Korea and Japan, biliary drainage via a percutaneous approach is preferred for patients with hilar cholangiocarcinoma. [50] [51] [52] Preoperative biliary drainage can be a reasonable choice under certain conditions such as right lobectomy for Bismuth type IIIA or IV hilar cholangiocarcinoma or preoperative portal vein embolization with chemoradiation therapy. 53 Endoscopic palliation, combined percutaneous and endoscopic procedures (especially after a failed endoscopic procedure), or percutaneous drainage alone have been used for unresectable malignant hilar tumors. 54 In general, endoscopic management is the preferred treatment for palliation. Previous studies suggest that SEMS is superior to plastic stents for the treatment of hilar malignancy. [55] [56] [57] [58] The placement of SEMS is especially recommended for patients with expected survival more than 3 months or with infected bile duct. CSEMS is not appropriate for palliative drainage of hilar malignant obstruction because it occludes the contralateral biliary duct and has migration issues. 12 Although the use of unilateral or bilateral stents is debated, the important step is draining more than 50% of the liver volume, which reportedly results in a greater decrease in bilirubin level, lower incidence of early cholangitis, and longer patient survival. 59 Bismuth classification is useful for endoscopic stent placement planning. In patients with Bismuth type I cholangiocarcinoma, only one stent in the common duct is appropriate for drainage. Palliation of the other lesion types, especially types III and IV, risks incomplete drainage and requires multiple stents. 36, 52, 60 Additionally, contrast injection into an undrained biliary system can lead to a higher rate of post-procedure cholangitis and decrease the survival rate. 61 Prophylactic antibiotics are needed routinely. Bilateral stent insertion preserves the functional liver volume, decreases the potential risk of cholangitis, and lowers complications when there are bilateral infected ducts, extending patient survival. 60 The Asia-Pacif-ic Consensus developed an algorithm for palliative biliary drainage in hilar cholangiocarcinoma (Fig. 1) . 52 However, an endoscopic approach may be considered as the initial strategy in actual clinical practice at many centers. Bilateral stenting is difficult and technically challenging. Bilateral biliary drainage with SEMS can be performed using two methods, the "side-by-side" and "stent in-stent" (also called "through-the-mesh") methods. The technical success rates are 73.3% and 100%, and the functional success rates are 75% and 100%, respectively. 62 Although the stent in-stent method seems to be theoretically more physiological due to suitable bile duct configuration, the selection of side-by-side versus stent-in-stent placement for hilar biliary obstruction is still controversial. In a recent study, the side-by-side method resulted in a higher incidence of complications, but tended to be superior in cumulative stent patency. 63 Newly designed SEMS such as the Y-configured stent (Y type biliary Niti-S stent; Taewoong Inc., Seoul, Korea and M-Hilar and K-Hilar stents; Standard Sci-Tech Inc., Seoul, Korea) have a relatively high success rate for hilar biliary strictures. [64] [65] [66] Modifying the stents and improvement of the skill or technique in the stent-in-stent method are expected to lead to wider use of these stents. Additionally, minor (limited) endoscopic sphincterotomy may be a better strategy to achieve successful stent placement requiring complex procedural techniques. Further high-quality comparative studies are needed to determine the best therapy using these stent types and procedures.
NOVEL STENTS
Both plastic stents and SEMS are continuously undergoing functional enhancements. Additionally, a variety of functional stents including antimigratory stents, antireflux stents, drug-eluting stents, radioactive stents, and bioabsorbable stents are currently under development to overcome the limitations of existing stents.
With FCSEMS, migration is a major problem. Several newly designed stents prevent stent migration; anchoring flaps or flared stent ends are commonly used. 67, 68 Studies using FCSEMS with either an anchoring flap or a flared end at the proximal end of the stent reported that the anchoring flap design might be superior in terms of efficacy and a lower migration rate to the flared end. 69, 70 Transpapillary SEMS placement may induce duodeno-biliary reflux and lead to cholangitis. FCSEMS with antireflux valves attached at the distal ends is being developed to prevent reflux. Although the results are not always positive due to malfunction of the attached valve, antireflux stents are worthy of further investigation. 71 Regarding malignant biliary obstruction, drug-eluting stents coated with an antitumor agent that inhibits tumor ingrowth may improve stent patency.
14 However, previous studies using paclitaxel-eluting CSEMS
have not yet shown a definite advantage in stent patency and patient survival. 72 Additional studies are currently being performed to investigate the appropriate drug concentration and stent membrane type and shape. [73] [74] [75] Bioabsorbable stents theoretically may not require stent removal and can be combined with antibacterial or antitumor materials. 68, 76 They might be particularly useful for benign biliary strictures and bile duct leaks, but require additional studies and outcome data.
CONCLUSIONS
Biliary stents have been used in various malignant and benign biliary obstructions. SEMS has been traditionally used for inoperable malignant biliary obstructions. Regardless of the number of stents deployed, drainage of more than 50% of the liver volume is important for longer patient survival, and endoscopic bilateral metallic stenting could be the preferred treatment for hilar malignant biliary strictures with highgrade obstruction. Although guidelines are lacking, FCSEMS has been proposed as a reasonable alternative therapeutic option for benign biliary disease. Currently, various types of SEMS such as antimigratory, antireflux, drug-eluting, radioactive, and bioabsorbable stents are being studied. Many studies are at a stage of early investigation or in early clinical experiments. However, a customized functional stent appropriate to the disease characteristics of the patient and various other situations should be considered in the future.
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